Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Arrowhead Publishers | The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape

The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape

The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).

According to Arrowhead Publishers’ new report The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral market is set to grow to over US$25.0 billion by 2012 driven by the uptake of newer anti-retroviral agents in combination therapy and the launch of ten new products for the treatment of HIV and hepatitis which will address the need of treatment-resistant patients. This will help to stem the tide of this prevalent and often lethal killer in our society today.

Pharmaceutical companies continue to develop a new generation of antiretroviral agents to overcome the issue of drug and cross-resistance. Meanwhile new drug classes are under evaluation that increases the virologists armory against these endemic and often deadly infectious diseases.

This report examines each of the antiviral classes in turn, assessing the market potential and encompassing the major infectious diseases to which they are applicable.

The following product classes are analyzed in this report:

* antisense

* attachment, entry and fusion inhibitors

* DNA polymerase inhibitors

* integrase inhibitors

* interferons

* maturation inhibitors

* monoclonal antibodies

* neuraminidase inhibitors

* NS3 protease inhibitors

* nucleoside reverse transcriptase inhibitors

* nucleotide reverse transcriptase inhibitors

* protease inhibitors

* reverse transcriptase inhibitors

* RNA polymerase inhibitors

The report assesses the overall antiviral market, key classes, the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category and by leading players, therapies and their products and analyzes market trends.

The report examines promising pipeline products and their potential impact on the prescription of current and new antiviral agents and the future antiviral market.

Key features of this report:

* Overview of the antiviral market, including main infectious agents, therapeutic drug classes and key players.

* In-depth analysis of different classes of antiviral agents, including key antiretroviral and antiviral agents and compares drugs within each class.

* Comprehensive facts and figures for the antiviral market, including main players and therapeutic break-downs.

* Future trends in the antiviral marketplace, driven by drug resistance, cross-resistance and patient demographics.

* Outlook for the antiviral market, including the emergence of novel therapies, new combination therapies and the impact of generics.

Publication Date: May 17, 2007

Pages: 186

PDF Format
Table of Contents

Price

Single User PDF $2499.00

Corporate Wide Licence PDF $5499.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions